KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Invested Capital: 2009-2025

Historic Invested Capital for Rigel Pharmaceuticals (RIGL) over the last 15 years, with Sep 2025 value amounting to $147.4 million.

  • Rigel Pharmaceuticals' Invested Capital rose 1106.90% to $147.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $147.4 million, marking a year-over-year increase of 1106.90%. This contributed to the annual value of $10.6 million for FY2024, which is 149.31% up from last year.
  • According to the latest figures from Q3 2025, Rigel Pharmaceuticals' Invested Capital is $147.4 million, which was up 41.30% from $104.3 million recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' Invested Capital ranged from a high of $147.4 million in Q3 2025 and a low of -$31.8 million during Q3 2023.
  • Moreover, its 3-year median value for Invested Capital was -$16.9 million (2024), whereas its average is $11.7 million.
  • In the last 5 years, Rigel Pharmaceuticals' Invested Capital tumbled by 664.62% in 2023 and then surged by 1,106.90% in 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Invested Capital (Quarterly) stood at $30.4 million in 2021, then tumbled by 144.83% to -$13.6 million in 2022, then plummeted by 57.28% to -$21.4 million in 2023, then skyrocketed by 149.31% to $10.6 million in 2024, then soared by 1,106.90% to $147.4 million in 2025.
  • Its Invested Capital stands at $147.4 million for Q3 2025, versus $104.3 million for Q2 2025 and $33.4 million for Q1 2025.